Drug intelligence / Profile preview

CVL-300x

Development stage: Unknown
Lead developer: Convelo Therapeutics
Modality: Small Molecules

Overview

CVL-300x is a small molecule drug candidate developed by Convelo Therapeutics. It acts as an inhibitor of the CYP51 family (Cytochrome P450 family 51), which is involved in sterol biosynthesis. The primary therapeutic area under investigation for this compound is multiple sclerosis, with potential applications in other immune system and nervous system diseases. As of the latest update, its highest development status globally is at the Discovery stage[1].

Targets

CYP51A1 (Sterol 14α-demethylase)

Beyond the preview

Go deeper on CVL-300x.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CVL-300x.

Explore the full profile